Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 25, 2015 3:23 PM ET

Pharmaceuticals

Company Overview of Shasun Pharmaceuticals Ltd

Company Overview

Shasun Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and enteric coating excipients. The company offers API products in the areas of pain management and musculoskeletal, central nervous system, cardiovascular, hyperphosphataemia, anti-infective, gastrointestinal, gastrointestinal, and other areas, as well as is developing API products in the areas of anti-depressant and anti-Parkinson’s. It is also engaged in the contract research and manufacturing services business, which provides chemistry and analytical services; and offers formulation development and manufacturing services for solid dosage products to pharmaceutical customers. In ...

Batra Centre

3rd & 4th Floor

28, Sardar Patel Road

Guindy

Chennai,  600032

India

Founded in 1976

Phone:

91 44 4344 6700

Fax:

91 44 2235 0278

Key Executives for Shasun Pharmaceuticals Ltd

Managing Director, Chief Executive Officer, Wholetime Director, Member of Stakeholders Relationship Committee and Member of Risk Management Committee
Age: 61
Total Annual Compensation: $10.1M
Whole-Time Director and Member of Corporate Social Responsibility Committee
Age: 63
Total Annual Compensation: $6.5M
Wholetime Director and Member of Audit Committee
Age: 58
Total Annual Compensation: $6.4M
Compensation as of Fiscal Year 2014.

Shasun Pharmaceuticals Ltd Key Developments

Shasun Pharmaceuticals Ltd Announces the Resignation of Indira J. Parikh as Independent Director

Shasun Pharmaceuticals Ltd. announced that the Board of Directors of the company at its meeting held on February 05, 2015, approved the resignation of Prof. Indira J. Parikh, Independent Director from the Board with effect from February 05, 2015.

Shasun Pharmaceuticals Ltd Announces Unaudited Consolidated and Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Shasun Pharmaceuticals Ltd. announced unaudited consolidated and standalone earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, on consolidated basis, the company's net sales/income from operations was INR 3,100.5 million compared with INR 3,093.8 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 209.2 million compared with INR 203.7 million a year ago. Profit from ordinary activities before tax was INR 68.1 million compared with INR 129.6 million a year ago. Net profit was INR 61.4 million or INR 0.99 per diluted share compared with INR 130.4 million or INR 2.30 per diluted share a year ago. EBITDA was INR 398.3 million compared with INR 441.8 million a year ago. For the nine months, on consolidated basis, the company's net sales/income from operations was INR 9,158.5 million compared with INR 8,110.9 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 350.0 million compared with INR 174.3 million a year ago. Profit from ordinary activities before tax was INR 31.2 million compared with INR 95.1 million a year ago. Net profit was INR 16.0 million or INR 0.26 per diluted share compared with INR 198.1 million or INR 3.50 per diluted share a year ago. EBITDA was INR 873.2 million compared with INR 942.9 million a year ago. For the quarter, on standalone basis, the company's revenue was INR 2,732.9 million compared with INR 2,465.4 million a year ago. EBITDA was INR 465.6 million compared with INR 338.3 million a year ago. PAT was INR 191.0 million compared with INR 101.2 million a year ago. For the nine months, on standalone basis, the company's revenue was INR 8,032.8 million compared with INR 6,457.3 million a year ago. EBITDA was INR 1,028.3 million compared with INR 735.5 million a year ago. PAT was INR 344.4 million compared with INR 241.7 million a year ago.

Shasun Pharmaceuticals Ltd to Report Q3, 2015 Results on Feb 05, 2015

Shasun Pharmaceuticals Ltd announced that they will report Q3, 2015 results on Feb 05, 2015

Similar Private Companies By Industry

Company Name Region
JK Pharmachem Asia
Sujatha Biotech Limited Asia
Parke-Davis Ltd. Asia
Sterling Synergy Systems Private Limited Asia
Bayer Zydus Pharma Private Limited Asia

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
February 7, 2015
Alivira Animal Health Ltd.
Merger/Acquisition
December 31, 2014
--
Merger/Acquisition
September 29, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Shasun Pharmaceuticals Ltd, please visit www.shasun.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.